Goldman downgrades Watson Pharma

Goldman Sachs dealt a blow to Watson Pharmaceuticals today, downgrading the generics maker to "sell" and recommending that investors short the stock. A Goldman analyst cited the potential for lower sales of the iron-deficiency drug Ferrlecit and the company's intent to expand overseas. Report